Bronchitis Treatment Market: Current Analysis and Forecast (2021-2027)

Bronchitis Treatment Market: Current Analysis and Forecast (2021-2027)

The global bronchitis treatment market is expected to witness a CAGR of around 5% during the forecast period (2021–2027). The rising prevalence of respiratory diseases such as asthma, COPD, and lung cancer, among others coupled with rising geriatric population is expected to drive the demand for effective bronchitis treatment. According to the world health organization (WHO), around 262 million people suffer from asthma, and nearly 3 million people die from chronic obstructive pulmonary disease (COPD). Additionally, Bronchitis is when the tubes that carry air to your lungs, called the bronchial tubes, get inflamed and swollen.

AstraZeneca PLC, Novartis AG, GlaxoSmithKline PLC, Dr. Reddy's Laboratories Ltd, Sanofi SA, Boehringer Ingelheim International GmbH, Pfizer Inc., Melinta Therapeutics, Lupin Limited, Cadila Healthcare Limited Services are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
"Amongst Type, Acute Bronchitis category to witness the fastest growth during the forecast period”

Based on type, the market is classified into acute bronchitis and chronic bronchitis. Amongst them, in 2020, the acute bronchitis category dominated the market and is expected to maintain its dominance throughout the forecast period. Acute bronchitis is an infectious viral infection that causes inflammation of the bronchial tubes. These tubes are the airways that carry air into your lungs. When these tubes get infected, they swell mucus (thick fluid) forms inside them. This narrows the airways, making it harder for breath-dependent patients. Furthermore, smoking is the main cause of chronic bronchitis. Therefore, an upsurge in the smoking populace is further expected to increase the need for bronchitis treatment. For instance, according to the Centers for Disease Control and Prevention (CDC), Nearly 40 million U.S. adults still smoke cigarettes, and an estimated 2.55 million middle and high school students use at least one tobacco product, including e-cigarettes.
"Amongst Drug Class, Bronchodilator category is expected to witness significant growth in the Bronchitis treatment market”

Based on drug class, the market is bifurcated into antibiotics, anti-inflammatory, bronchodilator, and others. Among them, in 2020, the bronchodilator category dominated the market and is expected to maintain its dominance throughout the forecast period. This is mainly due to the rising prevalence of chronic obstructive pulmonary disease (COPD), smoking, pollution, respiratory diseases, etc. According to the World health organization (WHO), Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.
"Amongst Distribution Channel, Hospitals Pharmacies category is expected to witness significant growth in the Bronchitis treatment market”

Based on distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and others. In 2020, the hospitals and clinics category accounted for the majority share during the forecast period. This can be ascribed to the fact that hospitals and clinics are the first step in any disease diagnosis. In addition, the growth of this market segment includes increased incidences of respiratory diseases, growth in the geriatric population, COPD, bronchitis, asthma, smoking, and rising air pollution all over the world. Additionally, smoking is the major reason for complications of bronchitis. Furthermore, according to the office of diseases prevention and health promotion (ODPHP), Currently, more than 25 million people in the United States have asthma. Approximately 14.8 million adults have been diagnosed with COPD, and approximately 12 million people have not yet been diagnosed. Furthermore, governments across the works are investing heavily in the development and improvement of healthcare infrastructure. Moreover, rising patient footfall in hospitals owing to ease of accessibility to most healthcare services in one place is likely to boost the segment growth.
"North America to witness significant growth during the forecast period”

For a better understanding of the market adoption of the Bronchitis treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America); Europe (Germany, United Kingdom, France, Spain, Italy, Rest of Europe); Asia-Pacific (China, Japan, India, Rest of Asia-Pacific); and the Rest of World. In 2020. North America held an extensive market share owing to the increasing prevalence of respiratory diseases, growth in the geriatric population, COPD, bronchitis, asthma, smoking, and rising air pollution coupled with the rising geriatric population in the region. According to the US Census Bureau analysis, the elderly population is expected to nearly double in the next 25 years. In addition, according to World Population Ageing, in 2019, the elderly population of North America was 59.9 million which is expected to reach 96.2 million by 2050.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.